One aspect of the invention resides in a monolithic sustained release composition of glipizide for patients with non-insulin dependent diabetes mellitus that exhibits a breakdown after ingestion by a patient in conformity with a zero-order kinetic. The present invention provides a composition of a glipizide and a hydrocolloid forming agent and optimally other auxiliary excipients for the sustained release of glipizide. It is preferable that the hydrophilic material comprises at least 50% by weig...

A monolithic sustained release composition of glipizide for patients with non-insulin dependent diabetes mellitus that exhibits a breakdown after ingestion by a patient in conformity with a zero-order kinetic. A composition of a glipizide and a hydrocolloid forming agent and optimally other auxiliary excipients for the sustained release of glipizide. Hydrophilic material may comprise at least 50 % by weight of the composition. A process for producing the composition, which includes the steps of ...

Inclusion complexes of glipizide and a nonionic surfactant with cyclodextrin and cyclodextrin derivatives. A method of preparing the inclusion complexes of glipizide and a nonionic surfactant with cyclodextrin and cyclodextrin derivatives, by wetting cyclodextrin or a derivative thereof with a nonionic surfactant, and mixing the resulting mixture with glipizide. A pharmaceutical composition containing an inclusion complex of glipizide and a nonionic surfactant with cyclodextrin and cyclodextrin ...

A monolithic sustained release composition of glipizide for patients with non-insulin dependent diabetes mellitus that exhibits a breakdown after ingestion by a patient in conformity with a zero-order kinetic. A composition of a glipizide and a hydrocolloid forming agent and optimally other auxiliary excipients for the sustained release of glipizide. Hydrophilic material may comprise at least 50 % by weight of the composition. A process for producing the composition, which includes the steps of ...